EP2996702A1 - Extraits d'astragalus membranaceus, leur préparation et leur utilisation comme médicaments antihyperalgésiques et antiallodyniques - Google Patents

Extraits d'astragalus membranaceus, leur préparation et leur utilisation comme médicaments antihyperalgésiques et antiallodyniques

Info

Publication number
EP2996702A1
EP2996702A1 EP13730658.5A EP13730658A EP2996702A1 EP 2996702 A1 EP2996702 A1 EP 2996702A1 EP 13730658 A EP13730658 A EP 13730658A EP 2996702 A1 EP2996702 A1 EP 2996702A1
Authority
EP
European Patent Office
Prior art keywords
pain
extracts
astragalus membranaceus
extraction
extracts according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13730658.5A
Other languages
German (de)
English (en)
Inventor
Alessandro Mugelli
Anastasia KARIOTI
Annarita BILIA
Lorenzo DI CESARE MANNELLI
Fabio FIRENZUOLI
Eugenia Rosaria GALLO
Carla Ghelardini
Alessandra PACINI
Alfredo Vannacci
Matteo ZANARDELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Giellepi SpA
Original Assignee
Giellepi SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giellepi SpA filed Critical Giellepi SpA
Publication of EP2996702A1 publication Critical patent/EP2996702A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • Extracts of Astragalus membranaceus their preparation and use as antihyperalgesic and antiallodynic drugs
  • the present invention relates to the field of plant product extracts.
  • neuropathic pain As: "An unpleasant sensory and emotional experience that is associated with actual or potential tissue damage or otherwise described as such”. It is a major problem in neurology as it is frequent and often debilitating on account of its chronic nature.
  • oxaliplatin is a third generation platinum-organic compound that induces the appearance of a neuropathic syndrome characterised by paresthesia and dysesthesia of the extremities accompanied by cramps. These symptoms occur in 85-95% of patients treated. While the acute toxicity disappears within a few days of administration, repeated treatment induces a chronic form that does not subside in the interval between the treatment cycles (Gamelin et al., Semin Oncol 29, 2002; Extra et al. Semin Oncol 25, 1998; Andre et al., J Clin Oncol 17, 1999; Cersosimo Ann Pharmacother 39, 2005).
  • Oxa!iplatin induces two types of peripheral neuropathy, an acute and a chronic type both characterised by hyperalgesia and allodynia until there is impairment of daily activities.
  • This painful symptomatology is the main reason for suspension of antitumor therapy (Extra et alirri 1998; Andre et al., 1999; Gamelin et al., 2002; Cersosimo et al., 2005).
  • taxane-based antineoplastic therapy contemplates a distal, symmetrical, axonal, predominantly sensory neuropathy among the side effects (Argyriou, et al.. Critical Reviews in Oncology/Hematology 66:218-228, 2008).
  • Some epidemiological data reports an onset of peripheral neuropathy in 60% of patients taking taxanes. Even in this case, the symptoms most frequently reported by patients include paresthesia and motor peripheral neuropathies that determine pain in distal segments of the limbs.
  • Figure 1 shows the IR spectrum of the extract according to the invention
  • Figure 2 shows the spectrum obtained by nuclear magnetic resonance technique
  • Figure 3 shows the profile of the two-dimensional HETCOR spectrum (called HMQC).
  • Hydroalcoholic extracts of Astragalus membranaceus useful as antihyperalgesic and antiallodynlc drugs, are described.
  • Astragalus membranaceus is a plant belonging to the Fabacease family that has powerful antioxidant properties (Sheng et al., Chin. Med. J. 5:43-49, 2005, Li et al, Urol. Res. 34:277-282, 2006, Luo et al. Phytother. Res. 23:761-767, 2009) of which the dried root is used.
  • the extracts according to the invention are hydroalcoholic extracts substantially obtained following the methodologies known in this field.
  • Alcohols for the extraction Water or alcohol/water mixtures can be used as alcohols for the extraction; ethanol is one example of alcohol that can be used for the extraction.
  • the amount of alcohol is normally between 0 - 80% (calculated in volume with respect to the total volume of the mixture), preferably 70%.
  • Extraction is carried out at room temperature by maceration and under stirring for a few days in order to obtain an exhaustive extraction of the phytocomplex, possibly by renewing the solvent employed one or more times.
  • the extraction can be performed by percolation with hydroalcoholic solutions as defined above or for decoction.
  • the alcohol is subsequently evaporated and the aqueous solution is lyophilized thus obtaining the desired product.
  • the resulting solutions are pooled and the ethanol is evaporated with a rotary evaporator at low pressure.
  • the resulting aqueous solution is lyophilized thus obtaining a white-pale yellow powder that is analysed by various methods to obtain a fingerprint.
  • the powder obtained was analysed by infrared, by the nuclear magnetic resonance technique thus respectively obtaining the spectra set out in Figure 1 and 2.
  • HMQC profile of the two-dimensional HETCOR spectrum
  • the sample is prepared by mixing with nujol to obtain a preparation of semisolid consistency which under IR analysis has the following fingerprint:
  • HMQC profile of the two-dimensional HETCOR spectrum
  • the anomeric proton at 5.3 ppm has a cross-peak with an anomeric carbon ⁇ 92.0 ppm
  • the group of carbinolic proton signals in the area between 3 and 4 ppm has characteristic cross-peaks with the carbons falling within the area between 60.0 and 82.0 ppm, which correspond to the carbinolic carbons of the saccharides.
  • the signals at 60.0 ppm belong to the free methylenes (-CH2), while the signals at 82.0 ppm belong to the carbons on the positions of bonds in the polysaccharide chain.
  • the lyophilized extract thus obtained can then be formulated for administration, preferably in oral form and, if necessary, can see the addition of the usual excipients used in this type of formulation such as for example inorganic excipients (such as for example silica gel) or excipients of a polysaccharide nature (such as for example: maltodextrin or lactose).
  • excipients used in this type of formulation such as for example inorganic excipients (such as for example silica gel) or excipients of a polysaccharide nature (such as for example: maltodextrin or lactose).
  • hydroalcoholic extract only exerts its pain threshold increasing action in the cold plate test. It is interesting to observe that the hydroalcoholic extract of Astragalus membranaceus does not induce analgesia per se in the absence of a painful condition (Tab. 1 a, 1 b, 1 c).
  • the hydroalcoholic extract is also capable of improving the motor coordination of rats subjected to treatment with oxaliplatin.
  • Tab. 2 shows the antihyperalgesic effect of the hydroalcoholic extract under analysis at the dose of 300 mg kg '1 p.o. on paclitaxel-induced hyperalgesia evaluated in rats in the paw pressure test.
  • the hydroalcoholic extract of Astragalus membranaceus in animals is free of antihyperalgesic effect as regards some neuropathic pains such as for example pain induced by antiviral agents, loose ligation of the sciatic nerve and by experimental osteoarthritis induced by monoiodoacetate.
  • the histopathological analysis carried out on liver and kidney samples from rats subjected to co-treatment with oxaliplatin and hydroalcoholic extract of Astragalus membranaceus has shown an appreciable protective effect on the part of the plant extract under analysis in respect of the alterations consequent to the cytotoxic effect of the chemotherapeutic drug.
  • the pathological picture indicative of the presence of acute crescentic and/or focal segmental glomerulonephritis caused by treatment with oxaliplatin is significantly reduced by the administration of the hydroalcoholic extract of Astragalus membranaceus.
  • the administration of the hydroalcoholic extract of Astragalus membranaceus at a dose of 300 mg/kg p.o. once/day, in conjunction with oxaliplatin, has shown to have a statistically significant protective effect, in respect to the damage induced by chemotherapeutic drugs, at the level of the basal ganglia attached to the posterior roots.
  • the immunohistochemical evaluation has allowed us to use to highlight that the treatment in question was capable of increasing neuofilament expression levels (NF200) that were reduced due to the chemotherapeutic drug.
  • a normalisation of the increased expression in the nuclei of ganglion neurons induced by chemotherapy has also been highlighted for transcription factor ATF3 (activating transcription factor 3), which is subject to nuclear dislocation in the course of damage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des extraits hydroalcooliques d'Astragalus membranaceus, leur préparation et leur utilisation comme médicaments antihyperalgésiques et antiallodyniques
EP13730658.5A 2013-05-14 2013-05-14 Extraits d'astragalus membranaceus, leur préparation et leur utilisation comme médicaments antihyperalgésiques et antiallodyniques Withdrawn EP2996702A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/053914 WO2014184615A1 (fr) 2013-05-14 2013-05-14 Extraits d'astragalus membranaceus, leur préparation et leur utilisation comme médicaments antihyperalgésiques et antiallodyniques

Publications (1)

Publication Number Publication Date
EP2996702A1 true EP2996702A1 (fr) 2016-03-23

Family

ID=48670636

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13730658.5A Withdrawn EP2996702A1 (fr) 2013-05-14 2013-05-14 Extraits d'astragalus membranaceus, leur préparation et leur utilisation comme médicaments antihyperalgésiques et antiallodyniques

Country Status (2)

Country Link
EP (1) EP2996702A1 (fr)
WO (1) WO2014184615A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432162A (zh) * 2018-12-27 2019-03-08 大理大学 地八角提取物及其药物组合物和制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100482237C (zh) * 2004-11-18 2009-04-29 高普 多糖甙中药口服制剂及其制备方法
CN100574785C (zh) * 2007-08-03 2009-12-30 司马蕾 一种治疗神经病理性疼痛的复方中药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014184615A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109432162A (zh) * 2018-12-27 2019-03-08 大理大学 地八角提取物及其药物组合物和制备方法与应用

Also Published As

Publication number Publication date
WO2014184615A1 (fr) 2014-11-20

Similar Documents

Publication Publication Date Title
Chen et al. Osthole, a natural coumarin improves cognitive impairments and BBB dysfunction after transient global brain ischemia in C57 BL/6J mice: involvement of Nrf2 pathway
Madhuri et al. Antioxidant, immunomodulatory and anticancer activities of Emblica officinalis: an overview
RU2755478C2 (ru) Композиции, способы и медицинские композиции для лечения и поддержания здоровья печени
KR101865360B1 (ko) 간 치료 및 간 건강 유지를 위한 조성물과 의학 조성물
ES2597784T3 (es) Combinación de extracto de raíz de valeriana y aceite de lavanda para utilizar en el tratamiento de trastornos del sueño
CN105769891A (zh) 低极性稀有人参皂苷混合物及其用途
Haslan et al. The underlying mechanism of action for various medicinal properties of Piper betle (betel)
EP3391893A1 (fr) Composition médicamenteuse pour traiter la leucémie et son procédé de préparation
KR20240020687A (ko) 암의 예방 또는 치료를 위한 혼합 생약 추출물 및 도세탁셀의병용 요법
EP2606883A1 (fr) Utilisations de n-butylidenephthalide dans le traitement d'une lésion du foie et amélioration de la fonction hépatique
WO2014184615A1 (fr) Extraits d'astragalus membranaceus, leur préparation et leur utilisation comme médicaments antihyperalgésiques et antiallodyniques
Beagloo et al. The antioxidant and hepatoprotective effect of alcoholic extract of ginger against the cisplatin-induced oxidative stress in rats
CN101773532B (zh) 一种天名精总内酯提取物
CN108348566A (zh) 用于治疗肝脏和维持肝脏健康的组合物、方法和药物组合物
CN110585233B (zh) 一种抗肿瘤组合物及其制药用途
WO2019142062A2 (fr) Composition à base d'herbes synergique ayant une activité anti-proliférative
CN104082538B (zh) 用于防治猪流行性感冒的饲料
CN104116821B (zh) 一种抗炎镇痛的药物组合物及其用途
KR20140021903A (ko) 어성초 추출물을 포함하는 항염증 및 염증성 신경 퇴행성 질환 예방 또는 치료용 조성물
RU2010147395A (ru) Компартамент-специфическая комбинация растительных экстрактов из гинкго билоба и женьшеня, обладающая двойным действием
Waghulde et al. Comparative anti-inflammatory activity of aril extracts of punica granatum fruits
CN104888149A (zh) 治疗宫颈癌的药物及其制备工艺
TWI826039B (zh) 檳榔葉萃取物於治療或預防肝癌的醫藥用途
ITFI20110249A1 (it) Estratti di astragalus membranaceus loro preparazione ed uso come antiperalgesici ed antiallodinici.
CN105748553A (zh) 一种活血消肿解毒的中药组合物及其制备方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BILIA, ANNARITA

Inventor name: PACINI, ALESSANDRA

Inventor name: KARIOTI, ANASTASIA

Inventor name: MUGELLI, ALESSANDRO

Inventor name: GALLO, EUGENIA ROSARIA

Inventor name: GHELARDINI, CARLA

Inventor name: FIRENZUOLI, FABIO

Inventor name: ZANARDELLI, MATTEO

Inventor name: DI CESARE MANNELLI, LORENZO

Inventor name: VANNACCI, ALFREDO

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160719